Solian 100 mg/ml oral solution

Package leaflet: Information for the user

Introduction

Package leaflet: information for the patient

Solian 100 mg/ml oral solution

Amisulpride

Read the entire leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet as you may need to read it again.

• If you have any questions, ask your doctor or pharmacist.

• This medicine has been prescribed for you only, and you must not give it to others, even if they have the same symptoms as you, because it could harm them.

• If you experience any adverse effects, consult your doctor, pharmacist, or nurse, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet contents

1. What Solian 100 mg/ml oral solution is and what it is used for
2. What you need to know before taking Solian 100 mg/ml oral solution
3. How to take Solian 100 mg/ml oral solution
4. Possible adverse effects
5. How to store Solian 100 mg/ml oral solution
6. Contents of the pack and other information

1. What Solian 100 mg/ml oral solution is and what it is used for

Amisulpride belongs to a group of medicines called antipsychotics.

Solian 100 mg/ml oral solution is indicated for the treatment of schizophrenia.

2. What you need to know before taking Solian 100 mg/ml oral solution

Do not take Solian 100 mg/ml oral solution

• if you are allergic to the active substance or to any of the other components of this medicine (listed in section 6).
• if you have a tumour dependent on prolactin (a hormone secreted by the anterior pituitary gland that stimulates milk production in the mammary glands), for example, pituitary prolactinomas or breast cancer.
• if you have phaeochromocytoma (a tumour of the adrenal gland).
• if you are a child before puberty.
• if you are being treated with levodopa.

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before taking Solian 100 mg/ml oral solution,

• as with other antipsychotic medicines, neuroleptic malignant syndrome (a potentially life-threatening condition) may occur, characterized by high fever, muscle rigidity, disturbances of the nervous system (autonomic instability), altered consciousness (obnubilation), rhabdomyolysis (muscle breakdown associated with muscle pain), and increased levels of an enzyme called creatine phosphokinase (CPK). In cases of high fever, particularly when high doses are used, all antipsychotic medications including amisulpride should be discontinued.

Rhabdomyolysis has also been observed in patients without neuroleptic malignant syndrome.

• if you suffer from Parkinson's disease.

• if you have known cardiovascular disease or a family history of QT interval prolongation, and the use of neuroleptic medicines should be avoided.

• if you have risk factors for stroke.

• in elderly patients with psychosis associated with dementia who are being treated with antipsychotics (increased risk of death).

• in patients with risk factors for thromboembolism (see section “Possible side effects”);

• if you have a personal or family history of breast cancer.

• if a pituitary tumour is diagnosed, treatment with amisulpride should be discontinued;

• if you have established diabetes mellitus or risk factors for diabetes.

• if you have a history of seizures.

• if you have renal impairment.

• withdrawal symptoms (nausea, vomiting, or insomnia) have been reported after abrupt discontinuation of treatment at high doses. Psychotic symptoms and sudden recurrence of involuntary movement disorders such as akathisia (inability to remain still), dystonia (persistent involuntary contractions of muscles in one or more parts of the body), and dyskinesia (lack of coordination of movement) may also occur. Therefore, gradual withdrawal is recommended.

• as with other antipsychotic medicines, leukopenia, neutropenia, and agranulocytosis may occur. The onset of fever or unexplained infections may indicate these blood disorders (blood dyscrasias) (see section “Possible side effects”) and may require immediate blood testing.

• serious liver problems have been reported with Solian. Contact your doctor immediately if you experience fatigue, loss of appetite, nausea, vomiting, abdominal pain, or yellowing of the eyes or skin.

Taking Solian 100 mg/ml oral solution with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

Certain medicines may alter the effect of Solian, and therefore your doctor may need to adjust the dose during concomitant treatment.

The use of Solian with levodopa is contraindicated.

Amisulpride may oppose the effect of dopaminergic agonists (e.g. bromocriptine and ropinirole).

The use of alcohol-containing medicines together with Solian is not recommended, as amisulpride may enhance the central effects of alcohol.

It is important that you inform your doctor if you are currently taking any of the following medicines:

• Central nervous system depressants including narcotics, analgesics, sedating H1 antihistamines, barbiturates, benzodiazepines and other anxiolytics, clonidine and derivatives.
• Medicines to lower blood pressure.
• Clozapine.
• Medicines that prolong the QT interval such as: antiarrhythmics (quinidine, disopyramide, amiodarone, and sotalol), some antihistamines, other antipsychotics, and certain antimalarial medicines (mefloquine).
• Lithium salts.
• Sucralfate.
• Antacids.

Taking Solian 100 mg/ml oral solution with food and drinks

This medicine may enhance the effects of alcohol; therefore, alcoholic beverages are not recommended during treatment.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before taking this medicine.

Pregnancy:

Solian is not recommended during pregnancy or in women of childbearing potential who are not using contraceptive methods.

If you take Solian during the last three months of pregnancy, your baby may experience agitation, muscle rigidity and/or muscle weakness, involuntary tremors, numbness, breathing difficulties, or feeding problems. If your baby develops any of these symptoms, you should contact your doctor.

Breastfeeding:

You must not breastfeed while taking Solian. Talk to your doctor about the best way to feed your baby if you are taking Solian.

Use in children

The safety and efficacy of amisulpride have not been established in patients from puberty through 18 years of age: available data on the use of amisulpride in adolescents with schizophrenia are limited. Therefore, the use of amisulpride is not recommended from puberty through 18 years of age. In children before puberty, amisulpride is contraindicated.

Driving and use of machines

Solian 100 mg/ml oral solution may cause symptoms such as somnolence, dizziness, visual disturbances, blurred vision, and may reduce reaction capacity. These effects, as well as the underlying illness itself, may impair your ability to drive vehicles or operate machinery. Therefore, do not drive, operate machinery, or engage in other activities requiring special attention until your physician has assessed your response to this medication.

Solian 100 mg/ml oral solution contains potassium, sodium, propyl parahydroxybenzoate and methyl parahydroxybenzoate, and ethanol:

Patients with renal impairment or those on potassium-restricted diets should be aware that this medicinal product contains 208 mg (5.32 mmol) of potassium per 4 ml.

Patients on sodium-restricted diets should be aware that this medicinal product contains 13.2 mg (0.57 mmol) of sodium per 4 ml.

As this medicine contains propyl parahydroxybenzoate (E216) and methyl parahydroxybenzoate (E218) as excipients, it may cause allergic reactions (possibly delayed).

This medicine contains 2.9 mg of alcohol (ethanol) in each ml of oral solution, equivalent to 0.29% (p/v). The amount in one ml of oral solution of this medicine is equivalent to less than 0.07 ml of beer or 0.029 ml of wine.

The small amount of ethanol contained in this medicine does not produce any perceptible effect.

3. How to take Solian 100 mg/ml oral solution

Follow exactly the instructions for use of this medicine given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Remember to take your medicine. Your doctor will tell you how long to continue treatment and how to gradually increase the dose. Do not stop treatment abruptly, as symptoms of your illness may reappear.

Solian 100 mg/ml is a solution for oral administration.

Adults:

The dose should be adjusted according to your clinical response and tolerance to treatment.

A daily dose between 400 mg/day (4 ml) and 800 mg/day (8 ml) is recommended. In individual cases, the daily dose may be increased up to 1200 mg/day (12 ml).

The daily dose should be administered as a single dose, or divided into two doses if the total daily dose exceeds 400 mg.

Elderly patients:

Solian should be used with special caution due to the possible risk of hypotension (abnormally low blood pressure) and sedation. Your doctor will adjust the dose in case of renal insufficiency.

Patients with renal impairment:

Your doctor will adjust the dose.

If you take more Solian 100 mg/ml oral solution than you should

Contact your doctor immediately or go to the nearest hospital.

In case of overdose or accidental ingestion, contact the Toxicology Information Service, telephone 91 562 04 20.

If you take more than the prescribed dose, symptoms such as drowsiness, sedation and even coma, decreased blood pressure, and abnormal movements may occur. Cases of death have been reported, mainly in combination with other psychotropic agents.

If you forget to take Solian 100 mg/ml oral solution

Do not take a double dose to make up for forgotten doses.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, Solian 100 mg/ml oral solution may cause adverse effects, although not everyone experiences them.

If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet.

The adverse effects observed according to their frequency of occurrence: Very common (may affect more than 1 in 10 people); Common (may affect up to 1 in 10 people); Uncommon (may affect up to 1 in 100 people); Rare (may affect up to 1 in 1,000 people); Very rare (may affect up to 1 in 10,000 people); Frequency not known (cannot be estimated from the available data), are as follows:

Blood and lymphatic system disorders:

Uncommon: Leucopenia (reduced number of white blood cells) and neutropenia (reduction in a type of white blood cells, neutrophils) (see section “Warnings and precautions”).

Rare: Agranulocytosis (reduction in a type of white blood cells, granulocytes) (see section “Warnings and precautions”).

Immune system disorders:

Uncommon: Allergic reactions.

Endocrine disorders:

Common: Milk secretion, absence of menstruation, breast enlargement (in males), breast pain, and erectile dysfunction.

Rare: Benign pituitary tumour such as prolactinoma (see sections “Do not take Solian” and “Warnings and precautions”).

Metabolism and nutrition disorders:

Uncommon: Hyperglycaemia (increased blood glucose levels) (see section “Warnings and precautions”), increased blood triglycerides and cholesterol.

Rare: Hyponatraemia and syndrome of inappropriate antidiuretic hormone secretion.

Psychiatric disorders:

Common: Insomnia, anxiety, agitation, orgasmic dysfunction.

Nervous system disorders:

Very common: Tremor, rigidity, poverty of movement, increased salivation, inability to remain still while sitting, and lack of coordination of movements.

Common: Acute dystonia (torticollis, oculogyric crises (involuntary deviation of gaze to one side), contraction of masticatory muscles) and somnolence.

Uncommon: Rhythmic, involuntary movements of the tongue and/or face, after long-term administration, and epileptic seizures.

Rare: Neuroleptic malignant syndrome, a potentially life-threatening complication (see section “Warnings and precautions”).

Frequency not known: Restless legs syndrome (unpleasant sensation in the legs, temporarily relieved by movement, and symptoms worsen at the end of the day).

Eye disorders:

Common: Blurred vision (see section “Driving and use of machines”).

Cardiac disorders:

Uncommon: Bradycardia (slowing of the heart rate).

Rare: QT interval prolongation, ventricular arrhythmias such as torsades de pointes, ventricular tachycardia, which may lead to ventricular fibrillation or cardiac arrest, sudden death (see section “Warnings and precautions”).

Vascular disorders:

Common: Hypotension.

Uncommon: Increase in blood pressure.

Rare: Venous thromboembolism (a condition characterised by blood clotting in the veins), including pulmonary embolism, sometimes fatal, and deep vein thrombosis (see section “Warnings and precautions”).

Respiratory, thoracic and mediastinal disorders:

Uncommon: Nasal congestion and aspiration pneumonia (mainly associated with other antipsychotics and central nervous system depressants).

Gastrointestinal disorders:

Common: Constipation, nausea, vomiting, dry mouth.

Hepatobiliary disorders:

Uncommon: Liver tissue damage.

Skin and subcutaneous tissue disorders:

Rare: Angioedema (generalised urticaria accompanied by swelling of feet, hands, throat, lips and airways) and urticaria.

Frequency not known: Increased sensitivity of your skin to sunlight and ultraviolet light (photosensitivity).

Musculoskeletal and connective tissue disorders:

Uncommon: Bone disorders (osteopenia, osteoporosis).

Frequency not known: Rhabdomyolysis (muscle breakdown associated with muscle pain).

Renal and urinary disorders:

Uncommon: Urinary retention.

Pregnancy, puerperium and perinatal disorders:

Frequency not known: Withdrawal syndrome in newborns (see section “Pregnancy and breastfeeding”).

Investigations:

Common: Weight gain.

Uncommon: Increased liver enzymes, mainly transaminases.

Frequency not known: Elevated levels of creatine phosphokinase (a blood test indicating muscle damage).

Injury, poisoning and procedural complications:

Frequency not known: Falls due to reduced body balance, which sometimes result in fractures.

Important: You must seek immediate medical attention:

• if, during treatment with Solian 100 mg/ml oral solution, you experience any of the following symptoms: high fever, generalized muscle rigidity, rapid breathing, abnormal sweating, or decreased mental alertness, a potentially life-threatening condition known as neuroleptic malignant syndrome (see section “Warnings and precautions”).
• or if you notice an irregular heartbeat, dizziness, vertigo, difficulty breathing, or chest pain, as isolated cases have been reported of: serious ventricular arrhythmias such as torsades de pointes, ventricular tachycardia which may lead to atrial fibrillation or cardiac arrest, and fatal outcome (see section “Warnings and precautions”).

Reporting of Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Solian 100 mg/ml oral solution

No special storage conditions are required.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the container. The expiry date refers to the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Dispose of containers and unused medicines at the SIGRE collection point at your pharmacy. If in doubt, ask your pharmacist how to dispose of containers and medicines you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Solian 100 mg/ml oral solution

• The active substance is amisulpride.

• The other components are: caramel flavour (containing ethanol), concentrated hydrochloric acid for pH adjustment, sodium saccharin, sodium gluconate, glucono delta-lactone, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), potassium sorbate, and purified water.

Appearance of the product and contents of the pack

Solian 100 mg/ml is a yellow, transparent oral solution with a caramel odour. It is supplied in 60 ml amber glass bottles. Each ml of solution contains 100 mg of amisulpride.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

sanofi-aventis, S.A.

C/ Rosselló i Porcel, 21

08016 Barcelona

Spain

Manufacturer:

Unither Liquid Manufacturing

1-3 allée de la Neste Z.I. en Sigal

31770 Colomiers (France)

Date of the most recent revision of this leaflet: September 2023

Detailed information on this medicine is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/